Results 111 to 120 of about 1,987,834 (344)

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Data monitoring committees for clinical trials evaluating treatments of\n COVID-19 [PDF]

, 2020
Tobias Mütze, Tim Friede
openalex   +2 more sources

HiSNAP trial—a multicentre, randomised, open-label, blinded end point, safety and efficacy trial of conventional (300 mg/kg) versus higher doses of acetylcysteine (450 mg/kg and 600 mg/kg) in patients with paracetamol overdose in the UK: study protocol

BMJ Open
Introduction In overdose, a larger proportion of paracetamol (acetaminophen) is converted in the liver to the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI).
, Alasdair Gray, David M Wood, Jacqueline James, Keith Boath, Rajendra Raman, Matt Reed, Rachel O’Brien, Alison Grant, Sharon Tuck, Liza Keating, Craig Davidson, Christopher J Weir, Jonathan Carter, Stephen Lynch, James W Dear, Michael Eddleston, Lyle Moncur, Julia Grahamslaw, Katherine Oatey, Marianne Gillings, Lynsey Milne, Natalie Homer, Caroline Blackstock, Philippa Wright, Christopher Humphries, Alan Timmins, Laura Muir, Ruben Thanacoody, Ellise Clarke, Heather Robertson, Anna Miell, Chloe Haigh, Luisa Padovani, Karen Gray, Sandra Pirie, Christina Coventry, Amy Armstrong, Sian Irvine, Oliver Carlill, Donna Clark, Fraser Craig, Angela Crawford, Carlyn Davie, Judith Flemming, Marie-Claire Harris, Katy Letham, Malgorzata Litwin, Fiona McCurrach, Shona McDonald, Fraser McFadyen, Hazel Milligan, Victoria Minnis, Gillian Pickering, Rebecca Rielly, Emma-Beth Wilson, Lisa-Marie Butt, Kathleen Scullion, Claire Cheyne, Angela McGeough, Nikki McLaughlin, Fern Purdie, Sandee Beattie, Anna Borkowska, Katie Hamilton, Keith Jacques, Jeronimo Martin Ramirez, Vasilika Ntoko, Surinder Pandhor, Janine Ramsey, Maria Simpson   +70 more
doaj   +1 more source

Position Statement Executive Summary: Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus [PDF]

, 2013
Background: Multiple laboratory tests are used in the diagnosis and management of patients with diabetes mellitus. The quality of the scientific evidence supporting the use of these assays varies substantially.
Arnold, Mark, Bakris, George L., Bruns, David E., Horvath, Andrea Rita, Kirkman, M. Sue, Lernmark, Ake, Metzger, Boyd E., Nathan, David Matthew, Sacks, David Barry   +8 more
core   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

“You have to keep your nerve on a DMC.” Challenges for data monitoring committees in neonatal intensive care trials: qualitative accounts from the bracelet study [PDF]

, 2015
Claire Snowdon, Diana Elbourne, Peter Brocklehurst, Martin Ward Platt, Robert C. Tasker   +4 more
openalex   +1 more source

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

Molecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy, Jana Löptien, Cornelia Coith, Afroditi Nanou, Katharina Hintelmann, Pinnschmidt Hans, Cordula Petersen, Klaus Pantel, Sabine Riethdorf, Kerstin Borgmann, Harriet Wikman   +10 more
wiley   +1 more source

Data monitoring committees: history and their future [PDF]

, 2013
David L. DeMets
openalex   +1 more source

Clinical performance of the urine‐based TERT promoter AbsoluteQ Digital PCR for non‐invasive detection of bladder cancer

Molecular Oncology, EarlyView.
A urine‐based digital PCR assay targeting two hotspot TERT promoter variants detected bladder cancer with high sensitivity and no false positives in this case–control cohort. The streamlined AbsoluteQ workflow outperformed Sanger sequencing and supports non‐invasive molecular testing for bladder cancer detection.
Anna Nykel, Izabela Kubiak, Lena Rutkowska, Żaneta Kasprzyk, Łukasz Kępczyński, Michał Bednarek, Dariusz Sobieraj, Jacek Wilkosz, Piotr Kania, Adam Jędrzejczyk, Bogdan Kałużewski, Agnieszka Gach, Tadeusz Kałużewski   +12 more
wiley   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source